Zymeworks Appoints Scott Platshon As Acting Chief Investment Officer To Oversee Future Cash Flows From Ziihera and Other Licensed Assets

Zymeworks Inc., a biotechnology company developing a broad pipeline of multifunctional biotherapeutics while managing a portfolio of licensed healthcare assets, has announced the appointment of Scott Platshon as Acting Chief Investment Officer. In this new role, Mr. Platshon will report directly to Kenneth Galbraith, the company’s Chair and Chief Executive Officer, and work closely with him to oversee the company’s expected future cash flows from assets such as Ziihera (zanidatamab-hrii) and other licensed product candidates, including pasritamig, which is being advanced toward Phase 3 registration trials by Johnson & Johnson Innovative Medicine. 

He will also be responsible for leading the operational execution of Zymeworks’ strategy to aggregate and manage healthcare assets. As part of his appointment, Mr. Platshon has stepped down from Zymeworks’ Board of Directors. Because this is a part-time position, he will continue his role as a Partner at EcoR1 Capital, LLC, an investment firm focused on the biotechnology sector. Kenneth Galbraith noted that the company is in a strong strategic position following positive topline results from the Phase 3 HERIZON-GEA-01 trial, which evaluated zanidatamab in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra (tislelizumab). 

He explained that Zymeworks is now focused on building a diversified portfolio of revenue-generating assets to support long-term value creation. Mr. Galbraith highlighted that Mr. Platshon has played an important role in managing EcoR1’s investment in Zymeworks since joining the Board in early 2024 and has helped shape the company’s plans to integrate its R&D activities with a strategy centered on actively managing and growing its portfolio of revenue-producing healthcare assets. His investment background, deep understanding of the company, and strong global network make him well suited to help guide these initiatives.

Mr. Platshon has been with EcoR1 Capital since 2015 and has served as a Partner since 2020. Before joining EcoR1, he was an analyst at Aquilo Partners, a boutique life sciences investment bank based in San Francisco. He also serves on the boards of Kumquat Biosciences and Ajax Therapeutics. He holds a bachelor’s degree in Bioengineering from Stanford University. Mr. Platshon shared his enthusiasm for taking on this new role at Zymeworks, especially at a time of significant momentum for the company. 

He said he looks forward to contributing to Zymeworks’ long-term strategy, which aims to combine scientific innovation with financial strength. He added that the company’s revenue foundation—led by Ziihera, industry partnerships, and its internal R&D pipeline—creates strong opportunities to build a disciplined portfolio that supports sustainable value creation. He expressed excitement about working even more closely with the Zymeworks team and helping develop new financial pathways to deliver long-term returns for shareholders.